TB drug candidate SQ109 in the top five most promising Q1 drugs entering phase II trials
23 February 2011
Thomson Reuters reports on most promising drugs changing clinical phase in the first quarter of 2011. The SQ109, a novel anti-TB drug candidate that could shorten and simplify the tuberculosis (TB) treatment regimen, has been listed in the top five of most promising drugs entering phase II trials this quarter. SQ109 is one of the products being evaluated by the Pan-African Consortium for Evaluation of Anti-tuberculosis Antibiotics (PanACEA), funded by the European and Developing Countries Clinical Trials Partnership (EDCTP).